Efficacy of pregabalin in neuropathic pain in paediatric oncological patients

…, H Oslejskova, T Kepak, P Mazanek… - European journal of …, 2009 - Elsevier
OBJECTIVE: To evaluate the safety and efficacy of pregabalin in the management of
chemotherapy-induced neuropathic pain in patients with childhood solid tumors and leukaemia. …

Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience

…, J Skotáková, K Husek, A Martincekova, P Mazánek… - Oncology, 2012 - karger.com
Background: The outcome of children with refractory/relapsed malignancies remains poor
and novel therapies are urgently required. One of the promising approaches is metronomic …

Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study

…, K Zitterbart, V Kadlecova, P Mazanek - Oncology Research …, 2006 - karger.com
To outline an outpatient-based treatment for children with relapsed solid tumors, who
already have been extensively pretreated, we defined a 4-drug protocol named COMBAT (…

Recurrent laryngeal papillomatosis: successful treatment with human papillomavirus vaccination

P Mudry, M Vavrina, P Mazanek… - Archives of disease in …, 2011 - adc.bmj.com
The authors describe the case of a 5-year-old girl with recurrent laryngeal papillomatosis (RLP)
due to human papillomavirus (HPV) type 11, who required frequent surgical treatment. …

[HTML][HTML] Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation …

V Dobrotkova, P Chlapek, P Mazanek, J Sterba… - BMC cancer, 2018 - Springer
For decades, retinoids and their synthetic derivatives have been well established anticancer
treatments due to their ability to regulate cell growth and induce cell differentiation and …

[HTML][HTML] Why differentiation therapy sometimes fails: molecular mechanisms of resistance to retinoids

P Chlapek, V Slavikova, P Mazanek, J Sterba… - International journal of …, 2018 - mdpi.com
Retinoids represent a popular group of differentiation inducers that are successfully used in
oncology for treatment of acute promyelocytic leukemia in adults and of neuroblastoma in …

[HTML][HTML] Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients

…, S Rahmann, J Bienertová-Vašků, P Mazánek… - JCI insight, 2018 - ncbi.nlm.nih.gov
In this study, the circulating miRNome from diagnostic neuroblastoma serum was assessed
for identification of noninvasive biomarkers with potential in monitoring metastatic disease. …

Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma

…, I Proleskovskaya, P Mazanek… - Pediatric hematology …, 2017 - Taylor & Francis
The metronomic therapy concept uses low doses of continuously applied chemotherapeutic,
anti-angiogenetic, and immunomodulating drugs. Twenty patients with recurrent and 3 with …

[HTML][HTML] Mutations in PIK3CAare infrequent in neuroblastoma

V Dam, BT Morgan, P Mazanek, MD Hogarty - BMC cancer, 2006 - Springer
Background Neuroblastoma is a frequently lethal pediatric cancer in which MYCN genomic
amplification is highly correlated with aggressive disease. Deregulated MYC genes require …

[HTML][HTML] Future paradigms for precision oncology

…, P Carmassi, E Rietman, O Slaby, P Mazanek… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Research has exposed cancer to be a heterogeneous disease with a high degree of inter-tumoral
and intra-tumoral variability. Individual tumors have unique profiles, and these …